falsefalse

Dissecting Perioperative Immunotherapy Approaches in Early-Stage NSCLC - Episode 3

Surgical Outcomes From CheckMate-77T With Perioperative Nivolumab in Resectable NSCLC

,

Wade T. Iams, MD, and Jessica Donington, MD, MSCR, discuss surgical outcomes from CheckMate-77T for perioperative nivolumab in resectable NSCLC.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: How Immunotherapy Is Affecting Perioperative Treatment Decisions in Early-Stage NSCLC
    EP. 2: Perioperative Nivolumab in Resectable NSCLC: Updated Data From CheckMate-77T
    Now Viewing
    EP. 3: Surgical Outcomes From CheckMate-77T With Perioperative Nivolumab in Resectable NSCLC
    EP. 4: Updated Findings From CheckMate-816 for Neoadjuvant Nivolumab Plus Chemo in Resectable NSCLC
    EP. 5: Factors Influencing Adjuvant Treatment Decisions in Early-Stage NSCLC
    EP. 6: How Immunotherapy Could Continue to Affect Early-Stage NSCLC Management
    EP. 7: Unmet Needs Research Aims to Address in Early-Stage NSCLC

    Related Content:

    Dissecting Perioperative Immunotherapy Approaches in Early-Stage NSCLCOncLive News Network®Lung CancerImmuno-Oncology
    Dr Halmos on Treatment Sequencing in Relapsed/Refractory NSCLC
    Immunotherapy and T-Cell–Directed Therapy Expand Treatment Approaches in Small Cell Lung Cancer
    Unmet Needs Research Aims to Address in Early-Stage NSCLC
    x